Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma Inc. was a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases affecting bone health and blood vessel function. Its news centered on the PPi-Adenosine Pathway, the ENPP1 Fc fusion protein enzyme replacement therapy INZ-701, and clinical development for ENPP1 Deficiency, with additional references to related mineralization and vascular conditions.
Company updates also covered ENERGY trial data, disease natural-history publications, operating and financial results, program prioritization, healthcare-conference participation, governance and capital-structure matters, and the completed acquisition of Inozyme by BioMarin Pharmaceutical in July 2025.
Inozyme Pharma (Nasdaq: INZY) announced the appointment of Yves Sabbagh, Ph.D., as the new senior vice president and chief scientific officer, marking a significant leadership change. Dr. Sabbagh brings over 20 years of experience in rare genetic disorders and mineral metabolism. He will focus on expanding Inozyme's proprietary pipeline. The company also confirmed the retirement of former CSO David Thompson, who will transition to a senior advisor role. Inozyme plans to enhance its R&D capabilities with new laboratory space in Boston.
Inozyme Pharma reported its Q2 2020 financial results, highlighting an upsized IPO that raised $128.8 million in July 2020. The company submitted its first IND for INZ-701 for treating ENPP1 deficiency, but the FDA placed the clinical trial on hold pending toxicity study reports. They expect trials to begin in early 2021. Cash reserves increased to $63.9 million by June 30, 2020, bolstered by IPO proceeds. R&D expenses rose to $7.9 million, reflecting intensified development activities. The net loss amounted to $9.5 million for the quarter.
Inozyme Pharma has successfully closed its initial public offering, selling 7,000,000 shares at $16.00 each, totaling $112 million, along with an additional 1,050,000 shares, bringing gross proceeds to $128.8 million. This offering marks a significant milestone as Inozyme's shares began trading on Nasdaq under the symbol 'INZY' on July 24, 2020. The underwriters for the offering included well-known firms such as BofA Securities and Cowen. Inozyme is focused on developing therapeutics for rare diseases linked to abnormal mineralization.